Non-invasive, Wearable Multi-parameter System for the Early Prediction of Cognitive Decline and Dementia in Older Adults

Mild Cognitive Impairment Clinical Trial

Official title:

Development of an Innovative, Non-invasive, Wearable Multi-parameter System for the Early Prediction of Cognitive Decline and Dementia in Older Adults

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04262674
• Other study ID #: 5213.00187
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 23, 2019
• Est. completion date: July 2021

Study information

• Verified date: February 2021
• Source: Empa, Swiss Federal Laboratories for Materials Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project develops an innovative screening system and prediction model to detect preclinical symptoms of cognitive impairment and predict the potential development of mild cognitive impairments and dementia in older adults. The earliest possible detection of preclinical symptoms is prerequisite to improve the efficacy of subsequent preventative non-pharmacological, life-style and exercise related, personalized treatment interventions.

Description:

BACKGROUND: Early detection of preclinical symptoms and prediction of potential development of mild cognitive impairment (MCI) and Alzheimer's disease (AD) could improve non-pharmacologic, life-style and exercise related preventative interventions' efficacy and slow-down disease progression. To achieve this goal, discriminating the earliest preclinical stage of MCI/AD from healthy state would be necessary. However, this is still challenging and current clinical methods are not feasible for preventative screening in larger populations of older adults, as they involve invasive sampling of molecular blood or cerebrospinal fluid biomarkers, as well as expensive brain imaging and extensive neuropsychological testing. Recently, several non-invasive alternative measures, including electroencephalography (EEG), gait analysis, heart rate variability (HRV), and core body temperature (Tc), were shown to be associated with preclinical symptoms of MCI/AD and to predict disease progression. AIM: The investigators aim to combine these measures in a novel non-invasive multi-parameter prediction model, which better reflects multimodal symptomatology compared to currently used methods and, therefore, allows discriminating healthy persons from MCI state with adequate sensitivity (i.e. >80%). METHODS: A cohort of 85 older adults, ≥65 years of age, including healthy persons and patients with MCI, will be recruited. Assessments will be performed at baseline, after 2 months (within these two 2 months one group will follow a cognitive-motor training intervention, while the other serves as passive control), and at 12-month follow-up. Assessments include EEG, gait analysis, HRV, and Tc at rest and during walking, and will be compared to reference measures of MCI status, including neuropsychological tests, to develop the prediction model and evaluate its sensitivity.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 82
• Est. completion date: July 2021
• Est. primary completion date: May 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• participants have to be older than 65 years of age
• cognitively healthy or diagnosed with MCI
• able to walk at least 8 minutes for gait analysis, with or without walking aids
• live independently or in a retirement home (classified 0, 1, or 2 within the Swiss classification system for health-care requirements BESA-levels [German abbreviation for: Bewohner-Einstufungs- und Abrechnungs-System; level 0 meaning the person does not need care or treatment; level 1 to 2 meaning, the person only needs little care or treatment])
• sign informed consent

Exclusion Criteria:

• previously diagnosed dementia, e.g. Alzheimer's disease
• recent head injury
• judgment by the participant's primary care physician will be required in the case of acute or instable chronic diseases (e.g. stroke, diabetes) and rapidly progressing or terminal illnesses Additional exclusion criteria for the subgroup of 15 participants who would agree to take

the telemetric gastrointestinal temperature pill:

• history of operations and/or disease related to the gastrointestinal tract within last 5 years
• implanted medical device
• planned MRI examination
• nausea, vomiting, constipation or abdominal pain within 1 months prior to the day of planned measurement

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Dementia
• Healthy Aging
• Mild Cognitive Impairment

Intervention

Other:
• Cognitive-motor training
Simultaneous cognitive-motor training and strength training

Locations

Country	Name	City	State
Switzerland	Empa	St.Gallen	SG

Sponsors (3)

Lead Sponsor	Collaborator
Empa, Swiss Federal Laboratories for Materials Science and Technology	ETH Zurich, Geriatrische Klinik St. Gallen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Electroencephalography (EEG)	EEG frequency bands (Hz) will be assessed during 10 minutes at rest in a seated position (5 min eyes closed, 5 min eyes open) and will be recorded using a wearable system covering the frontal, parietal, temporal, and occipital cortex and integrating 20 gel-pad electrode channels. The assessment will be continued during the subsequent gait protocol which consists of 8 minutes of walking back and forth at preferred speed on a 20 m track.	30 minutes
Primary	Gait speed analysis with inertial sensors	The gait protocol consists of 8 minutes of walking back and forth at preferred speed on a 20 m track. Thereby, walking speed (m/s) will be assessed using inertial sensors attached to the feet.	15 minutes
Primary	Gait variability analysis with inertial sensors	The gait protocol consists of 8 minutes of walking back and forth at preferred speed on a 20 m track. Thereby, step length variability (%) and step time variability (%) will be assessed using inertial sensors attached to the feet.	15 minutes
Primary	Heart rate variability (HRV) indices SDNN and RMSSD with two-lead electrocardiogram chest belt	The HRV indices SDNN (ms) and RMSSD (ms) will be assessed during 10 minutes in a seated position, using a two-lead electrocardiogram chest belt.	10 minutes
Primary	Heart rate variability (HRV) index HF power with two-lead electrocardiogram chest belt	The HRV index HF power (ms^2) will be assessed during 10 minutes in a seated position, using a two-lead electrocardiogram chest belt.	10 minutes
Primary	Body temperature (T) with temperature sensors (thermistors)	T will be assessed under controlled climatic conditions (22°C/40% relative humidity) measuring skin T (°C) at the scapula and the the ribs (lateral) using temperature sensors (thermistors) during 10 minutes sitting and 8 minutes walking as described above.	30 minutes
Secondary	Cognitive performance with neuropsychological tests	Neuropsychological tests will be performed to assess general cognitive performance (Quick Mild Cognitive Impairment screen), episodic memory (associative memory, Face-Name Associative Memory Exam, FNAME-12 test), semantic verbal fluency (category and letter fluency test), and executive functions (Trail Making Tests A/B, Stroop Test). The score of each test will be standardized and added up into a combined score of cognitive performance (z-score).	1 hour
Secondary	Core body temperature (Tc) with telemetric gastrointestinal temperature pill	In a subgroup of 15 participants, Tc (°C) will be recorded with a telemetric gastrointestinal temperature pill over a period of 16 hours.	16 hours